Teva seeks to raise up to $25 billion in bond sale to finance Allergan deal

15 July 2016

Teva Pharmaceutical Industries (NYSE: TEVA) will raise between $20 billion and $25 billion in a multi-currency bond sale to pay for its $40.5 billion acquisition of the generics business of Ireland-incorporated company Allergan (NYSE: AGN).

Reports said that the Israeli generics giant was hoping to raise this sum in the next week, having disclosed its intentions in a US Securities and Exchange Commission filing.

Calls are taking place with investors across the world to finance what is a complex takeover of the Allergan unit, particularly due to the conditions placed on the deal to prevent the merged entity from breaching competition rules.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK